Search - tctmd.com

Displaying 221 - 240 of 1775

Sort: Relevancy | Date

News Conference News EuroPCR 2024

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

Michael O'Riordan

May 15, 2024

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

Remote Monitoring in Real-world HF Cuts All-Cause Mortality: TELESAT-HF

Michael O'Riordan

May 12, 2024

News Daily News

Certain Periprocedural MIs Don’t Matter, New Data Allege

Michael O'Riordan

May 09, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Daily News

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Michael O'Riordan

April 04, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Advertisement

Young, Low-risk Patients Fare Well With TAVI, but Beware the Bicuspids

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Delays to Echo and Diagnosis Spell Poor Early Outcomes in Suspected HF

Remote Monitoring in Real-world HF Cuts All-Cause Mortality: TELESAT-HF

Certain Periprocedural MIs Don’t Matter, New Data Allege

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

FDA Approves Bioresorbable Scaffold for BTK Lesions

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content